<?xml version="1.0" encoding="UTF-8"?>
<p id="Par59">In general, PBRER periodicities and submission frequencies for newly authorised medicinal products in a country should follow ICH E2C and/or EU-GVP Module VII [
 <xref ref-type="bibr" rid="CR16">16</xref>] recommendations and be based upon the DLP calculated from the IBD i.e. 6-month periodicity the first 2 years after approval, then annually for the subsequent 3 years.
</p>
